Clinical Trial Update: Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of exenatide for hypothalamic obesity after craniopharyngioma therapy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniopharyngioma
• Hypothalamic Obesity

Drugs mentioned

• EXENATIDE (EXENATIDE)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Craniopharyngiomas, Hypothalamic Obesity | Phase 3 | Status: COMPLETED